LIGAND PHARMACEUTICALS (LGND:NASDAQ)
$274.41 -2.57 (-0.9279%)
Analysed LIGAND PHARMACEUTICALS (LGND:NASDAQ) News Sources
Ligand Reports Second Quarter 2026 Financial Results
06-08-2026
yahoo.com
This Biotech Dealmaker — Tied To Merck, Travere — Is In A Profit-Taking Zone
06-08-2026
yahoo.com
Ligand Pharmaceuticals Q2 Earnings Call Highlights
06-08-2026
marketbeat.com
Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary
06-08-2026
moby.co
Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highlights: Royalty Revenue Surges ...
06-08-2026
yahoo.com
Ligand (LGND) Q2 2026 Earnings Call Transcript
13-08-2026
fool.com
Ligand Pharmaceuticals (LGND) Reaffirms 2026 Guidance, Is The Stock Fully Priced?
13-08-2026
yahoo.com
Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run
14-08-2026
yahoo.com
Breakout Watch: Savvy Investors Bet Millions On Royalty-Fueled Pharma Stock
14-08-2026
yahoo.com
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
26-08-2026
marketbeat.com
What is the current price of LIGAND PHARMACEUTICALS (LGND:NASDAQ)?
The current price of LIGAND PHARMACEUTICALS (LGND:NASDAQ) is $274.41.
LIGAND PHARMACEUTICALS (LGND:NASDAQ) absolute price change since previous trading day?
The absolute price change of LIGAND PHARMACEUTICALS (LGND:NASDAQ) since the previous trading day is $-2.57.
LIGAND PHARMACEUTICALS (LGND:NASDAQ) percentage price change since previous trading day?
The percentage price change of LIGAND PHARMACEUTICALS (LGND:NASDAQ) since the previous trading day is -0.9279%.
What is the most recent average sentiment score for LIGAND PHARMACEUTICALS (LGND:NASDAQ)?
The most recent average sentiment score for LIGAND PHARMACEUTICALS (LGND:NASDAQ) is 88 out of 100.
What is the most recent average sentiment for LIGAND PHARMACEUTICALS (LGND:NASDAQ)?
The most recent sentiment for LIGAND PHARMACEUTICALS (LGND:NASDAQ) is .
SEC-8K** Filing Available For LIGAND PHARMACEUTICALS (LGND:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.